Excelsior Medical Co., Ltd. (TPE:4104)
Taiwan · Delayed Price · Currency is TWD 72.70
+0.50 (0.69%)
Sep 18, 2026, 1:30 PM CST
Excelsior Medical Ratios and Metrics
Market cap in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 17, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 13,600 | 14,000 | 14,052 | 13,757 | 10,019 | 8,130 | |
Market Cap Growth | -7.07% | -0.37% | 2.15% | 37.31% | 23.23% | 2.67% |
Enterprise Value | 14,873 | 15,358 | 11,054 | 14,022 | 9,593 | 6,612 |
Last Close Price | 72.20 | 75.85 | 72.85 | 68.46 | 48.07 | 36.93 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 17, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 14.82 | 17.37 | 18.22 | 18.43 | 15.01 | 13.39 |
Forward PE | - | 17.03 | 17.81 | 15.71 | 15.71 | 11.84 |
PS Ratio | 1.48 | 1.59 | 1.65 | 1.67 | 1.39 | 1.24 |
PB Ratio | 1.03 | 1.19 | 1.24 | 1.26 | 0.97 | 0.83 |
P/TBV Ratio | 1.42 | 1.53 | 1.58 | 1.61 | 1.23 | 1.06 |
P/FCF Ratio | 31.19 | - | 5.96 | - | 21.52 | 10.42 |
P/OCF Ratio | 25.53 | - | 5.69 | 128.44 | 15.73 | 8.60 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 17, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 1.62 | 1.75 | 1.30 | 1.70 | 1.34 | 1.01 |
EV/EBITDA Ratio | 10.27 | 16.62 | 11.68 | 16.19 | 12.94 | 9.21 |
EV/EBIT Ratio | 13.18 | 21.11 | 14.67 | 19.95 | 15.81 | 11.11 |
EV/FCF Ratio | 34.11 | - | 4.69 | - | 20.61 | 8.47 |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 17, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 0.18 | 0.18 | 0.13 | 0.13 | 0.08 | 0.08 |
Debt / EBITDA Ratio | 2.32 | 2.08 | 1.36 | 1.49 | 0.98 | 0.96 |
Debt / FCF Ratio | 5.53 | - | 0.61 | - | 1.74 | 0.98 |
Net Debt / Equity Ratio | -0.16 | -0.12 | -0.32 | -0.18 | -0.23 | -0.31 |
Net Debt / EBITDA Ratio | -2.32 | -1.49 | -3.83 | -2.27 | -3.26 | -4.19 |
Net Debt / FCF Ratio | -4.86 | 0.96 | -1.54 | 101.91 | -5.20 | -3.86 |
Asset Turnover | 0.47 | 0.45 | 0.44 | 0.48 | 0.46 | 0.45 |
Inventory Turnover | 5.26 | 4.97 | 5.12 | 5.45 | 5.48 | 5.90 |
Quick Ratio | 1.66 | 1.41 | 1.29 | 1.38 | 1.44 | 1.66 |
Current Ratio | 1.95 | 1.67 | 1.47 | 1.60 | 1.66 | 1.88 |
Return on Equity (ROE) | 8.62% | 8.37% | 8.72% | 8.70% | 7.84% | 7.47% |
Return on Assets (ROA) | 2.27% | 2.31% | 2.45% | 2.54% | 2.40% | 2.56% |
Return on Invested Capital (ROIC) | 5.74% | 6.58% | 7.47% | 6.74% | 6.77% | 7.30% |
Return on Capital Employed (ROCE) | 4.70% | 5.70% | 6.20% | 6.20% | 5.70% | 5.90% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 17, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Earnings Yield | 6.58% | 5.76% | 5.49% | 5.43% | 6.66% | 7.47% |
FCF Yield | 3.21% | -10.30% | 16.77% | -0.14% | 4.65% | 9.60% |
Dividend Yield | 5.92% | 5.67% | 5.22% | 5.04% | 6.56% | 7.80% |
Payout Ratio | 90.41% | 77.05% | 76.67% | 72.45% | 74.02% | 81.37% |
Buyback Yield / Dilution | -9.17% | -0.04% | 0.01% | 0.09% | 0.05% | -0.34% |
Total Shareholder Return | -3.10% | 5.63% | 5.23% | 5.12% | 6.61% | 7.45% |